The Association Between Serum Adiponectin Level and Glycemic Control

Aim: In last decades we recognize that the fat tissue isn't only a depot also an active endocrine tissue. The fat cell isn't a passive cell, it has an unsteady volume that changes according to daily energy uptake, and releases cytokines and hormones to extracelluler fluid. Patients with type 2 diabetes have distinctly increased atherosclerotic risk. This risk is associated with hyperglycemia, dyslipidemia and increased inflamation. Adiponectine that only secretes from adipose tissue, has a suspected role in this process. In this trial we looked for if there is any effect of adiponectin on glycemic control. Material and Method: The patients had been divided in three groups; diabetics with good glycemic control (n: 20), diabetics with bad glycemic control (n: 34) and non diabetics (n: 19). All patients age, sex, history of diabetes, BMI, waist circumference, fat mass, fat % had recorded then serums had taken for adiponectin and HbA1c assesment. Results: There was no correlation with adiponectine and HbA1c. Serum adiponectine levels were similar in three groups (659,29 +/- 98,57; 694,09 +/- 144,85; 609,5 +/- 168,24; p: 0,117). Discussion: The results showed that there is no significant effect of adiponectin on glycemic control contrary to expectations. The low levels of serum adiponectin isn't cause of the metabolic syndrome and insulin resistance, it's the result of the process that results in metabolic syndrome.